An updated analysis of the phase III EGF 104900 trial demonstrated some interesting findings. Combining Trastuzumab with Lapatinib – dual HER blockade, in patients with metastatic breast cancer who had progressed on anthracyclines, taxanes and trastuzumab, improved overall survival without significant adverse events. This is in spite of a 50% cross over from the control group to the dual HER blockade group. This may be a telling tale of how individuals with advanced metastatic breast cancer can benefit with targeted therapy.
Bottom Ad
Advertisement
Subscribe
